Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 290 entries
Sorted by: Best Match Show Resources per page
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.

Oncotarget

Chen CY, Chen YY, Chen JJW, Chen KY, Ho CC, Shih JY, Chang YL, Yu CJ, Yang PC.
PMID: 28977913
Oncotarget. 2017 Jun 28;8(37):61901-61916. doi: 10.18632/oncotarget.18717. eCollection 2017 Sep 22.

Previous studies have suggested that astrocyte-elevated gene-1 (AEG-1) contributes to the mechanisms of resistance to various chemotherapeutics. In this study, we investigated whether AEG-1 expression level correlated with that of thymidylate synthase (TS), as higher TS expression is known...

Cite
Chen CY, Chen YY, Chen JJW, et al. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. Oncotarget. 2017;8(37):61901-61916doi: 10.18632/oncotarget.18717.
Chen, C. Y., Chen, Y. Y., Chen, J. J. W., Chen, K. Y., Ho, C. C., Shih, J. Y., Chang, Y. L., Yu, C. J., & Yang, P. C. (2017). Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. Oncotarget, 8(37), 61901-61916. https://doi.org/10.18632/oncotarget.18717
Chen, Chung-Yu, et al. "Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression." Oncotarget vol. 8,37 (2017): 61901-61916. doi: https://doi.org/10.18632/oncotarget.18717
Chen CY, Chen YY, Chen JJW, Chen KY, Ho CC, Shih JY, Chang YL, Yu CJ, Yang PC. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. Oncotarget. 2017 Jun 28;8(37):61901-61916. doi: 10.18632/oncotarget.18717. eCollection 2017 Sep 22. PMID: 28977913; PMCID: PMC5617473.
Copy Download .nbib Format: NLM
lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer.

Molecular therapy. Nucleic acids

Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, Li C, Wang C.
PMID: 28918035
Mol Ther Nucleic Acids. 2017 Sep 15;8:356-369. doi: 10.1016/j.omtn.2017.07.007. Epub 2017 Jul 08.

One major reason for the failure of advanced colorectal cancer (CRC) treatment is the occurrence of chemoresistance to fluoropyrimidine (FU)-based chemotherapy. Long non-coding RNA HOTAIR has been considered as a pro-oncogene in multiple cancers. However, the precise functional mechanism...

Cite
Li P, Zhang X, Wang L, et al. lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer. Mol Ther Nucleic Acids. 2017;8:356-369doi: 10.1016/j.omtn.2017.07.007.
Li, P., Zhang, X., Wang, L., Du, L., Yang, Y., Liu, T., Li, C., & Wang, C. (2017). lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer. Molecular therapy. Nucleic acids, 8356-369. https://doi.org/10.1016/j.omtn.2017.07.007
Li, Peilong, et al. "lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer." Molecular therapy. Nucleic acids vol. 8 (2017): 356-369. doi: https://doi.org/10.1016/j.omtn.2017.07.007
Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, Li C, Wang C. lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer. Mol Ther Nucleic Acids. 2017 Sep 15;8:356-369. doi: 10.1016/j.omtn.2017.07.007. Epub 2017 Jul 08. PMID: 28918035; PMCID: PMC5537205.
Copy Download .nbib Format: NLM
Association between folate metabolism-related polymorphisms and colorectal cancer risk.

Molecular and clinical oncology

Kim JW, Jeon YJ, Jang MJ, Kim JO, Chong SY, Ko KH, Hwang SG, Oh D, Oh J, Kim NK.
PMID: 26137281
Mol Clin Oncol. 2015 May;3(3):639-648. doi: 10.3892/mco.2015.520. Epub 2015 Feb 27.

Folate has essential roles in DNA synthesis, repair and methylation. Folate metabolism-related gene variants may modulate the levels of this vitamin and affect the cancer risk. Thus, whether these polymorphisms play an important role in carcinogenesis, particularly colorectal cancer...

Cite
Kim JW, Jeon YJ, Jang MJ, et al. Association between folate metabolism-related polymorphisms and colorectal cancer risk. Mol Clin Oncol. 2015;3(3):639-648doi: 10.3892/mco.2015.520.
Kim, J. W., Jeon, Y. J., Jang, M. J., Kim, J. O., Chong, S. Y., Ko, K. H., Hwang, S. G., Oh, D., Oh, J., & Kim, N. K. (2015). Association between folate metabolism-related polymorphisms and colorectal cancer risk. Molecular and clinical oncology, 3(3), 639-648. https://doi.org/10.3892/mco.2015.520
Kim, Jong Woo, et al. "Association between folate metabolism-related polymorphisms and colorectal cancer risk." Molecular and clinical oncology vol. 3,3 (2015): 639-648. doi: https://doi.org/10.3892/mco.2015.520
Kim JW, Jeon YJ, Jang MJ, Kim JO, Chong SY, Ko KH, Hwang SG, Oh D, Oh J, Kim NK. Association between folate metabolism-related polymorphisms and colorectal cancer risk. Mol Clin Oncol. 2015 May;3(3):639-648. doi: 10.3892/mco.2015.520. Epub 2015 Feb 27. PMID: 26137281; PMCID: PMC4471578.
Copy Download .nbib Format: NLM
Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase.

OncoTargets and therapy

Asuncion Valenzuela MM, Castro I, Gonda A, Diaz Osterman CJ, Jutzy JM, Aspe JR, Khan S, Neidigh JW, Wall NR.
PMID: 25767396
Onco Targets Ther. 2015 Feb 26;8:495-507. doi: 10.2147/OTT.S79647. eCollection 2015.

New agent development, mechanistic understanding, and combinatorial partnerships with known and novel modalities continue to be important in the study of pancreatic cancer and its improved treatment. In this study, known antimetabolite drugs such as gemcitabine (ribonucleotide reductase inhibitor)...

Cite
Asuncion Valenzuela MM, Castro I, Gonda A, et al. Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. Onco Targets Ther. 2015;8:495-507doi: 10.2147/OTT.S79647.
Asuncion Valenzuela, M. M., Castro, I., Gonda, A., Diaz Osterman, C. J., Jutzy, J. M., Aspe, J. R., Khan, S., Neidigh, J. W., & Wall, N. R. (2015). Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. OncoTargets and therapy, 8495-507. https://doi.org/10.2147/OTT.S79647
Asuncion Valenzuela, Malyn M, et al. "Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase." OncoTargets and therapy vol. 8 (2015): 495-507. doi: https://doi.org/10.2147/OTT.S79647
Asuncion Valenzuela MM, Castro I, Gonda A, Diaz Osterman CJ, Jutzy JM, Aspe JR, Khan S, Neidigh JW, Wall NR. Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. Onco Targets Ther. 2015 Feb 26;8:495-507. doi: 10.2147/OTT.S79647. eCollection 2015. PMID: 25767396; PMCID: PMC4354452.
Copy Download .nbib Format: NLM
Clinical Experience With Pemetrexed in Breast Cancer.

Seminars in oncology

Martin M.
PMID: 28140044
Semin Oncol. 2006 Feb;33:15-18. doi: 10.1053/j.seminoncol.2005.07.027.

Alimta (pemetrexed) is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed possesses antitumor activity in several solid tumors, including...

Cite
Martin M. Clinical Experience With Pemetrexed in Breast Cancer. Semin Oncol. 2006;33:15-18doi: 10.1053/j.seminoncol.2005.07.027.
Martin, M. (2006). Clinical Experience With Pemetrexed in Breast Cancer. Seminars in oncology, 3315-18. https://doi.org/10.1053/j.seminoncol.2005.07.027
Martin, Miguel. "Clinical Experience With Pemetrexed in Breast Cancer." Seminars in oncology vol. 33 (2006): 15-18. doi: https://doi.org/10.1053/j.seminoncol.2005.07.027
Martin M. Clinical Experience With Pemetrexed in Breast Cancer. Semin Oncol. 2006 Feb;33:15-18. doi: 10.1053/j.seminoncol.2005.07.027. PMID: 28140044.
Copy Download .nbib Format: NLM
Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients.

Oncology letters

Huang Y, Guo X, Wang H, Zhu T.
PMID: 25435969
Oncol Lett. 2015 Jan;9(1):252-256. doi: 10.3892/ol.2014.2658. Epub 2014 Nov 03.

Chemotherapy represents an important treatment modality for lung adenocarcinoma. Thymidylate synthase (TS) is an essential enzyme in DNA synthesis, and its overexpression has been associated with reduced sensitivity to antifolate agents. The aim of the current study was to...

Cite
Huang Y, Guo X, Wang H, et al. Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients. Oncol Lett. 2014;9(1):252-256doi: 10.3892/ol.2014.2658.
Huang, Y., Guo, X., Wang, H., & Zhu, T. (2015). Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients. Oncology letters, 9(1), 252-256. https://doi.org/10.3892/ol.2014.2658
Huang, Yan, et al. "Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients." Oncology letters vol. 9,1 (2015): 252-256. doi: https://doi.org/10.3892/ol.2014.2658
Huang Y, Guo X, Wang H, Zhu T. Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients. Oncol Lett. 2015 Jan;9(1):252-256. doi: 10.3892/ol.2014.2658. Epub 2014 Nov 03. PMID: 25435969; PMCID: PMC4247065.
Copy Download .nbib Format: NLM
Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Experimental and therapeutic medicine

Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M.
PMID: 22977515
Exp Ther Med. 2011 May;2(3):393-397. doi: 10.3892/etm.2011.244. Epub 2011 Mar 21.

TAS-102 is an oral anticancer drug composed of trifluorothymidine (TFT) and TPI (an inhibitor of thymidine phosphorylase that strongly inhibits the biodegradation of TFT). Similar to 5-fluorouracil (5FU) and 5-fluoro-2'-deoxyuridine (FdUrd), TFT also inhibits thymidylate synthase (TS), a rate-limiting...

Cite
Suzuki N, Nakagawa F, Nukatsuka M, et al. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med. 2011;2(3):393-397doi: 10.3892/etm.2011.244.
Suzuki, N., Nakagawa, F., Nukatsuka, M., & Fukushima, M. (2011). Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Experimental and therapeutic medicine, 2(3), 393-397. https://doi.org/10.3892/etm.2011.244
Suzuki, Norihiko, et al. "Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks." Experimental and therapeutic medicine vol. 2,3 (2011): 393-397. doi: https://doi.org/10.3892/etm.2011.244
Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med. 2011 May;2(3):393-397. doi: 10.3892/etm.2011.244. Epub 2011 Mar 21. PMID: 22977515; PMCID: PMC3440718.
Copy Download .nbib Format: NLM
Prognostic significance of the mRNA expression of .

Experimental and therapeutic medicine

Sun S, Shi W, Wu Z, Zhang G, Yang BO, Jiao S.
PMID: 26622418
Exp Ther Med. 2015 Sep;10(3):937-941. doi: 10.3892/etm.2015.2636. Epub 2015 Jul 15.

The present study aimed to investigate the prognostic value of excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), class III β-tubulin (TUBB3) and thymidylate synthase (TYMS) in patients with non-small cell lung cancer (NSCLC) receiving platinum-based adjuvant...

Cite
Sun S, Shi W, Wu Z, et al. Prognostic significance of the mRNA expression of . Exp Ther Med. 2015;10(3):937-941doi: 10.3892/etm.2015.2636.
Sun, S., Shi, W., Wu, Z., Zhang, G., Yang, B. O., & Jiao, S. (2015). Prognostic significance of the mRNA expression of . Experimental and therapeutic medicine, 10(3), 937-941. https://doi.org/10.3892/etm.2015.2636
Sun, Shengjie, et al. "Prognostic significance of the mRNA expression of ." Experimental and therapeutic medicine vol. 10,3 (2015): 937-941. doi: https://doi.org/10.3892/etm.2015.2636
Sun S, Shi W, Wu Z, Zhang G, Yang BO, Jiao S. Prognostic significance of the mRNA expression of . Exp Ther Med. 2015 Sep;10(3):937-941. doi: 10.3892/etm.2015.2636. Epub 2015 Jul 15. PMID: 26622418; PMCID: PMC4533175.
Copy Download .nbib Format: NLM
Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report.

Cureus

Colton B, Hartley M, Manning MA, Carroll JE, Xiu J, Smaglo BG, Mikhail S, Salem ME.
PMID: 26918225
Cureus. 2016 Jan 12;8(1):e457. doi: 10.7759/cureus.457.

Gastroesophageal adenocarcinomas represent one of the top five most common types of cancer worldwide. Despite significant advancement, it is still not known which first-line chemotherapy option is best matched to an individual patient. The vast advances in molecular biology...

Cite
Colton B, Hartley M, Manning MA, et al. Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. Cureus. 2016;8(1):e457doi: 10.7759/cureus.457.
Colton, B., Hartley, M., Manning, M. A., Carroll, J. E., Xiu, J., Smaglo, B. G., Mikhail, S., & Salem, M. E. (2016). Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. Cureus, 8(1), e457. https://doi.org/10.7759/cureus.457
Colton, Bradley, et al. "Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report." Cureus vol. 8,1 (2016): e457. doi: https://doi.org/10.7759/cureus.457
Colton B, Hartley M, Manning MA, Carroll JE, Xiu J, Smaglo BG, Mikhail S, Salem ME. Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. Cureus. 2016 Jan 12;8(1):e457. doi: 10.7759/cureus.457. PMID: 26918225; PMCID: PMC4752374.
Copy Download .nbib Format: NLM
Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes.

ACS infectious diseases

Flannery EL, Wang T, Akbari A, Corey VC, Gunawan F, Bright AT, Abraham M, Sanchez JF, Santolalla ML, Baldeviano GC, Edgel KA, Rosales LA, Lescano AG, Bafna V, Vinetz JM, Winzeler EA.
PMID: 26719854
ACS Infect Dis. 2015 Aug 14;1(8):367-79. doi: 10.1021/acsinfecdis.5b00049. Epub 2015 Aug 03.

Understanding the mechanisms of drug resistance in Plasmodium vivax, the parasite that causes the most widespread form of human malaria, is complicated by the lack of a suitable long-term cell culture system for this parasite. In contrast to P....

Cite
Flannery EL, Wang T, Akbari A, et al. Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infect Dis. 2015;1(8):367-79doi: 10.1021/acsinfecdis.5b00049.
Flannery, E. L., Wang, T., Akbari, A., Corey, V. C., Gunawan, F., Bright, A. T., Abraham, M., Sanchez, J. F., Santolalla, M. L., Baldeviano, G. C., Edgel, K. A., Rosales, L. A., Lescano, A. G., Bafna, V., Vinetz, J. M., & Winzeler, E. A. (2015). Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS infectious diseases, 1(8), 367-79. https://doi.org/10.1021/acsinfecdis.5b00049
Flannery, Erika L, et al. "Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes." ACS infectious diseases vol. 1,8 (2015): 367-79. doi: https://doi.org/10.1021/acsinfecdis.5b00049
Flannery EL, Wang T, Akbari A, Corey VC, Gunawan F, Bright AT, Abraham M, Sanchez JF, Santolalla ML, Baldeviano GC, Edgel KA, Rosales LA, Lescano AG, Bafna V, Vinetz JM, Winzeler EA. Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infect Dis. 2015 Aug 14;1(8):367-79. doi: 10.1021/acsinfecdis.5b00049. Epub 2015 Aug 03. PMID: 26719854; PMCID: PMC4692371.
Copy Download .nbib Format: NLM
New Concepts for the Development and Use of Antifolates.

The oncologist

Chu E, Grem JL, Johnston PG, Allegra CJ.
PMID: 10387999
Oncologist. 1996;1(4):255-260.

Approximately one-third of all cases of colorectal carcinoma present in an advanced and, therefore, incurable stage. For these patients, the development of new chemotherapeutic strategies is of central importance. Biochemical modulation of 5-fluorouracil (5-FU) has resulted in approximately a...

Cite
Chu E, Grem JL, Johnston PG, et al. New Concepts for the Development and Use of Antifolates. Oncologist. 1996;1(4):255-260
Chu, E., Grem, J. L., Johnston, P. G., & Allegra, C. J. (1996). New Concepts for the Development and Use of Antifolates. The oncologist, 1(4), 255-260.
Chu, et al. "New Concepts for the Development and Use of Antifolates." The oncologist vol. 1,4 (1996): 255-260.
Chu E, Grem JL, Johnston PG, Allegra CJ. New Concepts for the Development and Use of Antifolates. Oncologist. 1996;1(4):255-260. PMID: 10387999.
Copy Download .nbib Format: NLM
Different Activities of 5-Hydroxy-dUMP and 5-Hydroxymethyl-dUMP in Thymidylate Synthase-Catalyzed Reaction in View of Molecular Modeling and Structural Studies.

Bioorganic chemistry

Jarmula A, Leś A, Rode W.
PMID: 10915553
Bioorg Chem. 2000 Jun;28(3):156-162. doi: 10.1006/bioo.2000.1172.

In order to explain different activities shown by 5-hydroxy-dUMP (substrate) and its close analogue 5-hydroxymethyl-dUMP (slow-binding inhibitor) in the reaction catalyzed by thymidylate synthase, studies have been undertaken involving (i) ab initio RHF simulations, (ii) comparative analysis of crystallographic...

Cite
Jarmula A, Leś A, Rode W. Different Activities of 5-Hydroxy-dUMP and 5-Hydroxymethyl-dUMP in Thymidylate Synthase-Catalyzed Reaction in View of Molecular Modeling and Structural Studies. Bioorg Chem. 2000;28(3):156-162doi: 10.1006/bioo.2000.1172.
Jarmula, A., Leś, A., & Rode, W. (2000). Different Activities of 5-Hydroxy-dUMP and 5-Hydroxymethyl-dUMP in Thymidylate Synthase-Catalyzed Reaction in View of Molecular Modeling and Structural Studies. Bioorganic chemistry, 28(3), 156-162. https://doi.org/10.1006/bioo.2000.1172
Jarmula, et al. "Different Activities of 5-Hydroxy-dUMP and 5-Hydroxymethyl-dUMP in Thymidylate Synthase-Catalyzed Reaction in View of Molecular Modeling and Structural Studies." Bioorganic chemistry vol. 28,3 (2000): 156-162. doi: https://doi.org/10.1006/bioo.2000.1172
Jarmula A, Leś A, Rode W. Different Activities of 5-Hydroxy-dUMP and 5-Hydroxymethyl-dUMP in Thymidylate Synthase-Catalyzed Reaction in View of Molecular Modeling and Structural Studies. Bioorg Chem. 2000 Jun;28(3):156-162. doi: 10.1006/bioo.2000.1172. PMID: 10915553.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 290 entries